Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer In Vivo Model

Qualigen Therapeutics, Inc. announced it has completed its in vivo efficacy analysis of QN-247 in solid tumors. Data demonstrated robust efficacy and no safety signals in a triple negative breast cancer model.